Domicilium Real Estate Fund III LP - 10 Jun 2026 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc. (ELOX)

Reporting relationship: 10%+ Owner
Issuer ticker: ELOX
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2026, 17:15:00 UTC
Prior SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: Domicilium Real Estate Fund III LP, By: Domicilium Real Estate Fund III GP LLC, its General Partner, By: /s/ Daniel Simon, Managing Member

Key filing fact

Domicilium Real Estate Fund III LP filed Form 4 for Eloxx Pharmaceuticals, Inc. (ELOX) on 17 Jun 2026.

Key facts

This page summarizes Domicilium Real Estate Fund III LP's Form 4 filing for Eloxx Pharmaceuticals, Inc. (ELOX).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 17 Jun 2026, 17:15.

Change

Previous filing in this sequence was filed on 17 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001945896 Primary reporting owner

Domicilium Real Estate Fund III LP

Relationship: 10%+ Owner
Address: 535 S. KIMBALL AVE, SUITE 140, SOUTHLAKE
Signature: Domicilium Real Estate Fund III LP, By: Domicilium Real Estate Fund III GP LLC, its General Partner, By: /s/ Daniel Simon, Managing Member
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELOX transaction

common stock, $0.01 par value per share

Other

Transaction value
Shares: +238,422
Change %
Price
Shares after: 238,422
Date: 10 Jun 2026
Ownership: See footnote
Footnotes: F1, F2

ELOX transaction

common stock, $0.01 par value per share

Other

Transaction value
Shares: +361,578
Change %
Price
Shares after: 361,578
Date: 10 Jun 2026
Ownership: See footnote
Footnotes: F1, F3

ELOX holding

common stock, $0.01 par value per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 14,285
Date: 10 Jun 2026
Ownership: See footnote
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELOX transaction Derivative

Pre-funded Warrant

Other

Transaction value
Shares: +238,422
Change %
Price
Shares after: 0
Date: 10 Jun 2026
Ownership: See footnote
Underlying class: common stock, $0.01 par value per share
Underlying amount: 238,422
Exercise price
Footnotes: F1, F2, F5

ELOX transaction Derivative

Pre-funded Warrant

Other

Transaction value
Shares: +361,578
Change %: +76%
Price
Shares after: 834,489
Date: 10 Jun 2026
Ownership: See footnote
Underlying class: common stock, $0.01 par value per share
Underlying amount: 361,578
Exercise price
Footnotes: F1, F3, F5

ELOX holding Derivative

Pre-funded Warrant

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 361,578
Date: 10 Jun 2026
Ownership: See footnote
Underlying class: common stock, $0.01 par value per share
Underlying amount: 0
Exercise price
Footnotes: F5, F6

ELOX holding Derivative

Pre-funded Warrant

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 611,317
Date: 10 Jun 2026
Ownership: See footnote
Underlying class: common stock, $0.01 par value per share
Underlying amount: 0
Exercise price
Footnotes: F5, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock.

Footnote F2

The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner.

Footnote F3

The securities are owned directly by BKJLAGG, LLC ("BKJLAGG") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium.

Footnote F4

The securities may be deemed to be indirectly beneficially owned by (i) Domicilium, and (ii) Daniel Simon, the managing member of Domicilium.

Footnote F5

The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

Footnote F6

The securities are owned directly by MSEK Charleston LLC ("MSEK") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to MSEK, and (ii) Daniel Simon, the managing member of Domicilium.

Footnote F7

The securities are owned directly by Bold Stroke Investments, LLC ("Bold Stroke") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to Bold Stroke, and (ii) Daniel Simon, the managing member of Domicilium.

SEC remarks

Domicilium Capital Partners LLC, Domicilium Real Estate Fund III GP LLC, Daniel Simon, BKJLAGG, LLC, MSEK Charleston LLC and Bold Stroke Investments, LLC will be reported as a Reporting Person on a subsequent Form 4 once CIK codes are received. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.